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Abstract
Following surgery of cholesteatoma, a patient developed a chronic
infection of the external auditory canal, including extended-spec-
trum b-lactamase producing Escherichia coli, which caused severe
pain. The application of cold atmospheric plasma resulted in a
signiﬁcant reduction in pain and clearance of bacterial carriage,
allowing antibiotics and analgesics to be ceased.
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Research Note
Cold atmospheric plasmas (CAPs) have demonstrated broad
bactericidal activity, regardless of the bacterial species and
resistance pattern in vitro and in vivo [1–3]. Plasma is the fourth
state of matter and high temperature plasmas have long been
used in the sterilization of medical equipment. The develop-
ment of CAPs now allows application to viable tissue. The
efﬁcacy of a CAP device in reducing bacterial carriage and pain
in a patient with chronic nasopharyngeal and external auditory
canal infection after cholesteatoma surgery is reported.
A 49-year-old man developed an acquired cholesteatoma of
the left tympanic cavity. Cholesteatoma is a rare cyst-like
growth formed from keratinizing stratiﬁed squamous epithe-
lium in the middle ear cleft or the petrous bone [4]. Surgery is
usually required because, although benign, cholesteatoma is
destructive and potentially life-threatening [5]. Under antibi-
otic prophylaxis (amoxicillin combined with clavulanic acid) the
patient underwent tympanoplasty, incus resection and recon-
structive surgery of the auditory channel. Subsequently,
chronic infection developed in the nasopharynx and external
auditory canal involving extended-spectrum b-lactamase-pro-
ducing (ESBL+) Escherichia coli and other bacteria (Proteus
mirabilis and Enterococcus faecalis). The infections were accom-
panied by severe pain, described as severe radiating headaches.
Over the 3 years post-surgery, repeated courses of
systemic co-trimoxazole were required in addition to regular
wax removal, topical antiseptics (e.g. octenidine) and hydrogen
peroxide 0.3% rinses. Aspirin did not relieve the headaches.
Co-trimoxazole was taken continuously for the 6 months
prior to presentation for CAP treatment.
After informed consent and with ethics committee
approval, daily weekday treatment was commenced to both
external auditory canals with 5-min cold atmospheric argon
plasma (Fig. 1) using the MicroPlaSter b device (built by
ADTEC Plasma Technology Co. Ltd., Hiroshima, Japan and
London, UK) (Microwave 2.46 GHz, 86 W; Ar 2.2 slm;
distance to external auditory meatus 2 cm) [6]. The naso-
pharynx was not treated as at the time respiratory tract CAP
exposure had been investigated only in ex vivo models [7].
Plasma treatment was given over 105 days in three blocks of
8, 16 and 19 (total 43) applications, respectively. Pain was
recorded using a visual analogue scale (VAS: range 0–10)
directly before and immediately after plasma applications.
Swabs for bacteriology were taken before, during and after
completion of the plasma treatment. Oral co-trimoxazole was
continued throughout the initial plasma treatment period,
ceasing after the 14th application of plasma. After ceasing the
systemic antibiotics, hydrogen peroxide (0.3%) rinsing contin-
ued and was performed twice during the ﬁnal treatment period.
No analgesics were required during the treatment period of
105 days. Although the headaches resolved, the patient
continued to describe an unpleasant soreness in the ear.
Plasma therapy was well tolerated and no side effects
occurred. Immediately after each plasma application there was
a mean pain reduction score of 1.1 with highly signiﬁcant
ongoing long-term improvement in pain (Fig. 2, p <0.01;
Wilcoxon rank t test). Pre-treatment pain was increased on
Mondays after the weekend break. One month after complet-
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ing CAP treatment, the patient remained highly satisﬁed with
the result.
During the total 105 day plasma-treatment period, bacte-
riology swabs from the external auditory canals and naso-
pharynx were all negative. Speciﬁcally no ESBL-producing E. coli
were detected. However 3 weeks after the ﬁnal plasma
application, Propionibacterium acnes was cultured from the
external auditory canal and ESBL(+) E. coli from the nasophar-
ynx.
Despite antibiotic prophylaxis, surgical site infections occur
in head and neck cancer surgery in over 30% of cases [8]. The
battle against antibiotic-resistant bacteria is one of the greatest
challenges in medicine in the 21st century and new approaches
are required to manage this problem [9, 10]. CAPs may be an
option as they can achieve high antibacterial activity without
the development of resistance (neither showing primary nor
secondary resistance development) or harmful effects on
surrounding human tissue [11–13]. The effects are probably
due to a synergy of physical–chemical features resulting in cell
wall permeabilization, penetration of reactive oxygen and
nitrogen species, and subsequent chemical reactions and
actions inside the cell [13].
The broad antimicrobial beneﬁt of CAP has been demon-
strated in randomized controlled clinical trials in patients with
chronic wounds [6, 14]. CAP application in Hailey-Hailey
disease resulted in successful clearance of Proteus mirabilis and
Candida albicans, and reduction in pain and burning sensations
due to the impetiginization [15].
In this case report, plasma application was limited by the
diffusion and penetration of the plasma into the external
auditory canal, and the inability to treat the nasopharynx.
However, even in a set-up not primarily developed for the
treatment of the external auditory canal, CAP treatment
resulted in the clearance of bacteria and relief of symptoms of
infection during treatment. Long-term antibiotics could be
ceased and quality of life improved to a patient’s satisfaction.
The current report will be advanced by future studies
demonstrating the efﬁcacy of CAP sources designed for treat
regions that are difﬁcult to treat, such as the external auditory
canal, and safety of use in the oral cavity.
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FIG. 1. Application of cold atmospheric argon plasma (MicroPlaSter
b) to the ear channel.
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